

## SUPPLEMENTARY DATA

Participating investigators: *Australia*: Gary Wittert, Royal Adelaide Hospital, Adelaide; Greg Fulcher, Royal North Shore Hospital, St. Leonards. *Guatemala*: Luis-Alberto Ramirez-Roca, Clinica Las Americas; Raul Barrera, Clinica Las Americas-A; Ronaldo Gonzalez, Endonutri. *Israel*: Eddy Karnieli, Rambam Medical Center, Haifa; Ilan Shimon, Beilinson MC, Petach Tikva; Julio Wainstein, Wolfson Hospital, Holon; Naftali Stern, Sourasky/Ichilov Hospital, Tel Aviv; Oscar Minuchin, Lin Medical Center, Haifa; Victor Vishlitzky, Meir Medical Center, Kfar Saba. *Mexico*: Carlos Dominguez Reyes, Centenario Hospital Miguel Hidalgo Aguascalientes, Aguascalientes; Enrique Morales, Centro en Investigacion de Enf. Cardiovasculares, Aguascalientes; Gerardo Gonzalez-Giron, Centro de Investigacion Clinica del Pacifico, Acapulco; Luis Alejandro Nevarez, Hospital Cima, Chihuahua; Melchor Alpizar-Salazar, Centro Especializado en Diabetes, Mexico City. *Peru*: Carlos Zubiate, Centro de Investigaciones Medicas Metabolic Care, Lima; Miguel Pinto, Oftalmolaser, Lima. *Romania*: Alexandrina Popescu, Ploiesti; Carmen Crisan, Mures; Mihaela Busegeanu, Ploiesti; Mihaela Vlaiculescu, Bucuresti; Nicolae Hancu, Cluj-Napoca; Silvana Constantinescu, Buzau. *Russia*: Alexander Khokhlov, Clinical Hospital, Jaloslave; Alexandr VasDreval, M.F. Vladimirsksiy Regional Scientific Research Institute, Moscow; Anatoly Kuzin, Chelyabinsk; Marina Ballyuzek, St-Petersburg Clinical Hospital of Russian Academy of Science, St. Petersburg; Olga Smirnova, Endocrinology Research Center of Rosmedtechnologies, Moscow; Valery Podzolkov, SEI HPE Moscow Medical Academy N.A.I.M. Sechenov of Russia, Moscow; Viacheslav Marasaev, Yaroslavl Regional Clinical Hospital, Yaroslavl; Vladimir Grinevich, State Institution 442 District Military Clinical Hospital, St. Petersburg; Vladimir Potemkin, Russian State Medical University, Moscow; Yuriy Uspenskiy, St. Petersburg State Medical Academy N.A. Mechanikov, St. Petersburg. *Slovakia*: Alena Gabrisova, Trencin; Anna Vargova, Levice; Ingrid Buganova, Zilina; Jan Truban, Dolny Kubin; Marek Macko, Presov. *Taiwan*: Chien-Wen Chou, Chi-Mei Medical Center, Tainan; Dee Pei, Cardinal Tien Hospital, Tapei County; Lee-Ming Chuang

National Taiwan University Hospital, Taipei; Shih-Te Tu, Changhua Christian Hospital, Changhua. *United States*: Milissa Cooper, Hope Research Institute, Phoenix, Arizona; Andrew Lewin, National Research Institute, Los Angeles, California; Robert Burton, Crest Clinical Trials, Santa Ana, California; Ronald Stegemoller, Avon Clinical Research, Avon, Indiana; Gregory Collins, Charlotte Clinical Research, Charlotte, North Carolina, Georges Tannoury, Specialty Medical Center, Pahrump, Nevada; Cynthia Strout, Coastal Carolina Research Center, Mount Pleasant, South Carolina; Philip Snell, Mountain View Clinical Research Inc., Greer, South Carolina; Douglas Denham and Mark Kipnes, Diabetes and Glandular Disease Research Associates, Inc., San Antonio, Texas; John Hoekstra, National Clinical Research, Richmond, Virginia.

## SUPPLEMENTARY DATA

**Supplementary Table 1.** Baseline and change from baseline at week 24 in exploratory endpoints

	Placebo n = 115	Taspoglutide 10 mg n = 112	Taspoglutide 20 mg n = 127
Diastolic blood pressure, mmHg, baseline (SE)	79.2 (0.8)	80.0 (0.8)	79.2 (0.7)
Change from baseline (95% CI)	-1.3 (-2.51, 0.002)	-0.5 (-1.80, 0.74)	-0.4 (-1.62, 0.81)
Systolic blood pressure, mmHg, baseline (SE)	130.7 (1.3)	130.0 (1.3)	131.3 (1.2)
Change from baseline (95% CI)	-2.4 (-4.35, -0.45)	-1.9 (-3.92, 0.04)	-2.5 (-4.37, -0.59)
Triglycerides, mmol/L, baseline (SE)	2.11 (0.09)	2.13 (0.10)	1.93 (0.09)
Change from baseline (95% CI)	-0.08 (-0.23, 0.06)	0.12* (-0.02, 0.26)	-0.15 (-0.28, -0.01)
HDL, mmol/L, baseline (SE)	1.19 (0.03)	1.21 (0.03)	1.25 (0.03)
Change from baseline (95% CI)	0.04 (-0.01, 0.09)	0.02 (-0.03, 0.06)	0.08 (0.04, 0.12)
LDL, mmol/L, baseline (SE)	3.14 (0.09)	3.38 (0.09)	3.29 (0.08)
Change from baseline (95% CI)	-0.06 (-0.19, 0.07)	-0.16 (-0.28, -0.03)	-0.19 (-0.31, -0.07)
Total cholesterol, mmol/L, baseline (SE)	5.19 (0.10)	5.44 (0.10)	5.33 (0.10)
Change from baseline (95% CI)	-0.08 (-0.24, 0.07)	-0.12 (-0.27, 0.03)	-0.21 (-0.35, -0.07)
hs CRP, mg/L, baseline (SE)	5.15 (0.72)	5.58 (0.74)	5.77 (0.69)
Change from baseline (95% CI)	-0.65 (-1.64, 0.35)	-0.90 (-1.86, 0.07)	-0.78 (-1.71, 0.15)
Waist circumference, cm, baseline	104.1 (1.2)	105.5 (1.2)	102.1 (1.2)
Change from baseline (SE)	-0.74 (0.68)	-1.52 (0.70)	-1.42 (0.63)
Hip circumference, cm, baseline	109.2 (1.2)	111.3 (1.2)	109.2 (1.1)
Change from baseline (SE)	-0.42 (0.74)	-1.47 (0.71)	-1.76 (0.68)
Waist/hip ratio, cm, baseline	0.95 (0.01)	0.95 (0.01)	0.94 (0.01)
Change from baseline (SE)	-0.002 (0.005)	0 (0.005)	0.002 (0.005)
Rescue medications needed, n (%)	12 (10.4)	2 (1.8)	1 (0.8)

\*P<0.05 vs placebo

SUPPLEMENTARY DATA

**Supplementary Table 2.** Baseline characteristics (ITT population, N = 354)

	Placebo n = 115	Taspoglutide 10 mg n = 112	Taspoglutide 20 mg n = 127
Male, n (%)	43 (37)	41 (37)	46 (36)
Age (years), mean (SD)	55.8 (8.5)	53.4 (9.6)	55.0 (10.4)
<65 years, n (%)	95 (83)	96 (86)	104 (82)
≥65 years, n (%)	20 (17)	16 (14)	23 (18)
Race, n (%)			
White	94 (82)	96 (86)	100 (79)
Asian	6 (5)	1 (1)	7 (6)
Black	0	0	1 (1)
Other	15 (13)	15 (13)	19 (15)
Ethnicity, n (%)			
Hispanic	37 (32)	40 (36)	38 (30)
Duration of diabetes (years), mean (SD)	2.3 (1.9)	2.8 (2.9)	2.1 (2.4)
<5 years, n (%)	103 (90)	90 (80)	112 (88)
5-10 years, n (%)	12 (10)	18 (16)	13 (10)
>10 years, n (%)	0	4 (4)	2 (2)
HbA1c (%), mean (SD)	7.6 (1.0)	7.5 (1.0)	7.7 (1.0)
HbA1c baseline ≥8%, n (%)	31 (27)	31 (28)	46 (36)
FPG (mmol/l), mean (SD)	8.6 (2.4)	8.8 (2.7)	9.0 (2.5)
Body weight (kg), mean (SD)	87.4 (19.3)	88.4 (17.8)	85.0 (17.0)
BMI ( $\text{kg}/\text{m}^2$ ), mean (SD)	32.1 (5.3)	33.2 (5.0)	31.7 (4.9)
Waist circumference, mean (SD)	104.1 (14.9)	105.5 (12.2)	102.1 (12.0)
Hip circumference, mean (SD)	109.2 (13.5)	111.2 (11.8)	109.1 (12.2)
Waist/hip ratio (SD)	0.95 (0.09)	0.95 (0.08)	0.94 (0.08)


## SUPPLEMENTARY DATA

**Supplementary Table 3.** Baseline and change from baseline in HOMA-B and Proinsulin-to-Insulin Ratio at week 24.

Parameter	Placebo <i>n</i> = 115	Taspoglutide 10 mg <i>n</i> = 112	Taspoglutide 20 mg <i>n</i> = 127
HOMA-B, baseline (SE)	59.8 (5.6)	70.3 (5.7)	56.9 (5.4)
Change from baseline (SE)	2.0 (16.3)	58.8 (16.3)*	65.2 (15.4)*
Proinsulin/Insulin Ratio, baseline (SE)	0.512 (0.029)	0.475 (0.030)	0.531 (0.028)
Change from baseline (SE)	-0.018 (0.024)	-0.143 (0.024)*	-0.106 (0.023)*


\**P*<0.05 vs. placebo

**Supplementary Figure 1.** Patient disposition



## SUPPLEMENTARY DATA

**Supplementary Figure 2.** Response rates ( $\text{HbA1c} \leq 7.0\%$  and  $\leq 6.5\%$ ) in patients receiving placebo, taspoglutide 10 mg and taspoglutide 20 mg.



**Supplementary Figure 3.** Change from baseline in  $\text{HbA1c}$  at week 24 by baseline  $\text{HbA1c}$  of  $<8\%$  and  $\geq 8\%$ .

